Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04493-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yuting Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed)/Guangd…. Hauptthemen laut MEDLINE: Mucin-1, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Induced Pluripotent Stem Cells. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Joint Funds for the Innovation of Science and Technology, Fujian Province, China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
BACKGROUND: MUC1 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but MUC1-targeted CAR-NK cells remain unexplored in this malignancy. METHODS: MUC1 expression was assessed by IHC in 90 ESCC specimens, 47 paired adjacent normal tissues, and normal human organs. MUC1-targeted CAR-NK cells were generated from an iPSC platform. Antitumor activity was evaluated against patient-specific ESCC organoids (PSOs), primary ESCC cells, KYSE150 and KYSE140 cells using live/dead staining, CCK-8, and xCELLigence assays. In vivo efficacy was assessed in a KYSE140 xenograft model. RESULTS: MUC1 was expressed in 70% (63/90) of ESCC cases versus 14.9% (7/47) of adjacent normal tissues (P 50% and > 80% tumor cell positivity, respectively. iPSC-derived MUC1 CAR-NK cells exhibited > 95% CAR expression across iPSC, progenitor, and mature stages. Compared with controls, MUC1 CAR-NK cells elicited potent, antigen-specific cytotoxicity against MUC1-expressing ESCC PSOs, primary cells, KYSE150, and KYSE140 in vitro and significantly suppressed KYSE140 xenograft growth in vivo. CONCLUSION: iPSC-derived MUC1-targeted CAR-NK cells exert robust and specific antitumor efficacy against human ESCC, supporting clinical translation of this off-the-shelf cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed)/Guangdong Engineering Technology Research Center of AI-Powered Precision Can…
- Guangdong Procapzoom Bioscience Inc., Guangzhou, China.
- Department of Thoracic Oncology, Cancer Hospital of Shantou University Medical College, Guangdong, China.
- Radiology Department, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Department of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. juping0128@163.com.
- Department of Pathophysiology, School of Basic Medical Sciences, Bengbu Medical University, Bengbu, China. juping0128@163.com.
Förderung
- the National Natural Science Foundation of China
- Joint Funds for the Innovation of Science and Technology, Fujian Province, China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Peng, Y., Guan, T., Xiao, Y., Lin, S., Wu, J., Lin, Y., Wang, J., Zeng, H., & Ma, C. (2026). Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04493-x
Vancouver
Peng Y, Guan T, Xiao Y, Lin S, Wu J, Lin Y, et al. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04493-x
BibTeX
@article{Peng2026,
author = {Peng, Yuting and Guan, Tian and Xiao, Yi and Lin, Shugeng and Wu, Jijun and Lin, Yan and Wang, Juping and Zeng, Haoyu and Ma, Changchun},
title = {Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04493-x}
}
EUVIMED